scholarly journals Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

2018 ◽  
Vol 35 (10) ◽  
pp. 1375-1382 ◽  
Author(s):  
N. Tofte ◽  
M. Lindhardt ◽  
K. Adamova ◽  
J. Beige ◽  
J. W. J. Beulens ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Mineralocorticoid Receptor ◽  
Low Risk ◽  
Receptor Antagonism ◽  
Urinary Proteomics ◽  
Mineralocorticoid Receptor Antagonism

Abstract 151: Mineralocorticoid Receptor Antagonism Prevents Vascular Remodeling in Mesenteric Arteries of Mice with type 2 Diabetes

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Marcondes A Silva ◽  
Stêfany B Cau ◽  
Carla P Manzato ◽  
Rhian M Touyz ◽  
Rita C Tostes
Keyword(s):  
Type 2 Diabetes ◽  
Mineralocorticoid Receptor ◽  
Structural Changes ◽  
Strain Curve ◽  
Mesenteric Arteries ◽  
Internal Diameter ◽  
Arterial Distensibility ◽  
Receptor Antagonism ◽  
Mineralocorticoid Receptor Antagonism

Diabetes induces important structural alterations in large and small arteries. Aldosterone, whose plasma levels are elevated in experimental and human diabetes may actively contribute to this process. We tested the hypothesis that mineralocorticoid receptor antagonism prevents diabetes-associated arterial structural changes. Male, 12-14 weeks old db/db mice, a model of type 2 diabetes, and their non-diabetic counterpart controls were treated with spironolactone (50mg/kg/day) or vehicle (1% ethanol) by gavage for 6 weeks. Structural and mechanical parameters were determined in mesenteric arteries with a pressurized myograph (Danish Myo Tech, Aarhus, Denmark). Spironolactone treatment did not affect blood pressure or fasting glucose levels [(mg/dL) 256.5 ± 31, db/db vs. 104 ± 2.3, control, p<0.05]. Arteries of vehicle-treated db/db mice (dbV) had a smaller internal diameter vs. spironolactone-treated db/db (dbS) and control mice (Con) [(μm) 253.9 ± 24.9 vs. 312.9 ± 10.4 dbS, 338.1 ± 32.6 Con; 120mmHg, p<0.05]. Spironolactone treatment prevented the increase of the thickness of the arterial wall [(μm) 23.2 ± 1.0 dbS vs. 30.4 ± 2.0 dbV, 19.4 ± 1.1 Con, 60 mmHg, p<0.05], of the wall:lumen ratio [0.089 ± 0.003 dbS vs. 0.136 ± 0.013 dbV, 0.069 ± 0.006 Con, 60 mmHg, p<0.05] and of the cross-sectional area [(μm2) 21302.7 ± 1791.7 dbS vs. 30189.1 ± 2314.8 dbV, 19144.4 ± 2331.2 Con, 40 mmHg, p<0.05]. The treatment with spironolactone also improved arterial distensibility in db/db mice [(% mmHg-1) 1.4 ± 0.03 dbS vs. 1.1 ± 0.1 dbV, 1.4 ± 0.02 Con, 40mmHg, p<0.05] and shifted the stress-strain curve to the right, indicating a decrease in vascular stiffness. Picrosirius red staining showed a lower collagen content in arteries from mice dbS [(arbitrary units) 4.1 ± 0.9 dbS vs. 6.9 ± 0.6 dbV, 2.8 ± 0.3 Con; p<0.05]. Preliminary data show that spironolactone treatment prevents augmented vascular c-Src and p38MAPK activation in db/db mice. Our data show that spironolactone treatment prevents inward hypertrophic remodeling in db/db mice, indicating that aldosterone importantly contributes to vascular damage associated with this disease.

scholarly journals SuO023EFFECTS OF VASOPRESSIN V2 RECEPTOR ANTAGONISM ON THE PROGRESSION OF DIABETIC NEPHROPATHY IN MOUSE MODEL OF TYPE 2 DIABETES

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii54-iii54
Author(s):  
Ray ElBoustany ◽  
Christopher Taveau ◽  
Catherine Chollet ◽  
Gilberto Velho ◽  
Lise Bankir ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Mouse Model ◽  
Receptor Antagonism ◽  
Vasopressin V2 Receptor ◽  
V2 Receptor

Overt Diabetic Nephropathy and Mineralocorticoid Receptor Antagonism

2007 ◽  
Vol 00 (1) ◽  
pp. 57
Author(s):  
Pieter M Jansen ◽  
Anton H van den Meiracker ◽  
◽  
Keyword(s):  
Diabetic Nephropathy ◽  
Mineralocorticoid Receptor ◽  
Receptor Antagonism ◽  
Mineralocorticoid Receptor Antagonism

scholarly journals Overt Diabetic Nephropathy and Mineralocorticoid Receptor Antagonism

2007 ◽  
Vol 00 (01) ◽  
pp. 57
Author(s):  
Pieter M Jansen ◽  
Anton H van den Meiracker ◽  
◽  
Keyword(s):  
Diabetic Nephropathy ◽  
Mineralocorticoid Receptor ◽  
Receptor Antagonism ◽  
Mineralocorticoid Receptor Antagonism

2306-PUB: Long-Term Effect of Liraglutide on the Prevention of Progression of Diabetic Nephropathy in Elderly Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2306-PUB
Author(s):  
MAMI YOSHIDA ◽  
AI YOSHIDA ◽  
ERIKO OH ◽  
NAOMUNE YAMAMOTO ◽  
EUN SASAKI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Elderly Patients ◽  
Term Effect ◽  
Long Term Effect
Sign in / Sign up

Export Citation Format

Share Document